Shared on01 May 25Fair value Increased 1.17%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Loading...
Expanding Global CNS And Orphan Therapies Will Unlock Future Potential
AN
AnalystConsensusTarget
Not Invested
Based on Analyst Price Targets
Published
24 Apr 25
Updated
01 May 25
AnalystConsensusTarget's Fair Value
US$12.67
57.1% undervalued intrinsic discount04 Sep
US$5.43
1Y
17.3%7D
6.5%1Y
17.3%7D
6.5%You can edit this narrative until May 12 5:59 AM. Then, changes will post as Updates.